Sarcoma of the Year: Desmoid Fibromatosis

(P 257) SELECTIVE INTRA-ARTERIAL DOXORUBICIN-ELUTING EMBOLIZATION FOR DESMOID FIBROMATOSIS: A COMBINED PROSPECTIVE AND RETROSPECTIVE STUDY

(P 258) TO TREAT OR NOT TO TREAT: AN AUDIT OF INITIAL MANAGEMENT OF PATIENTS WITH DESMOID TUMOURS AT A SPECIALISED CENTRE

(P 259) ASSOCIATION BETWEEN AREA DEPRIVATION INDEX AND INITIAL TREATMENT AMONG PATIENTS WITH DESMOID TUMORS

(P 260) BURDEN OF ILLNESS OF DESMOID TUMORS

(P 261) CLINICAL FEATURES AND TREATMENT OUTCOMES OF PATIENTS WITH DESMOID TUMORS: A LARGE SINGLE INSTITUTION RETROSPECTIVE SERIES

(P 262) CLINICAL RESULTS OF ACTIVE SURVEILLANCE FOR EXTRA ABDOMINAL DESMOID TYPE FIBROMATOSIS

(P 263) COMPARATIVE EFFECTIVENESS OF SYSTEMIC TREATMENTS IN DESMOID TUMORS

(P 264) DESMOID AND TRAUMA: REAL INCIDENCE AND MEDICOLEGAL ASPECTS OF CAUSALITY

(P 265) DEVELOPMENT OF THERAPEUTIC STRATEGY FOR DESMOID TUMOR WITH NOVEL PATIENT-DERIVED PRECLINICAL MODEL

(P 266) EFFICACY OF LIPOSOMAL DOXORUBICIN IN PATIENTS WITH INTRA- AND EXTRA-ABDOMINAL DESMOID FIBROMATOSIS

(P 267) EFFICACY OF SORAFENIB IN PRETREATED DESMOID TUMORS. EXPERIENCE OF A HIGH-VOLUME CENTER.

(P 268) INITIAL RESULTS OF PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS (DT)

(P 269) LANDSCAPE OF GENOMIC ALTERATIONS IN 115 PATIENTS WITH DESMOID FIBROMATOSIS IN THE AACR GENIE REAL WORLD DATABASE: CLINICAL IMPLICATIONS

(P 270) ORAL VINORELBINE ACTIVITY FOR PROGRESSIVE DESMOID FIBROMATOSIS TUMOURS IN YOUNG PATIENTS

(P 271) ORAL VINORELBINE IN DESMOID TUMOURS; A SINGLE CENTRE RETROSPECTIVE ANALYSIS

(P 272) PREGNANCY-ASSOCIATED DESMOID FIBROMATOSIS: A DUTCH MULTI-CENTRE RETROSPECTIVE ANALYSIS